ANDERNACH, Germany, October 13, 2025 /PRNewswire/ — LTS LOHMANN Therapie-Systeme AG (“LTS”), a leading pharmaceutical technology company, today announces the acquisition of Renaissance Lakewood, LLC (“Renaissance”), a U.S.-based contract development and manufacturing organization (CDMO) specializing in nasal sprays and sterile dosage forms.
With this acquisition, Renaissance’s facilities will become part of LTS’ global operational network, alongside LTS’ existing facilities in Andernach, Germany, West Caldwell, New Jersey, USA, St. Paul, Minnesota, USA and Netanya, Israel.
The acquisition of Renaissance marks an important step in LTS’ strategy to expand its capabilities in the CDMO space. Renaissance brings deep expertise, state-of-the-art manufacturing infrastructure and a talented workforce of approximately 500 employees. This move allows LTS to offer a broader range of drug delivery solutions and strengthens its position within the CDMO community.
Founded in 1979 and currently owned by RoundTable Healthcare Partners, Renaissance is headquartered in Lakewood, New Jersey. The Company operates multiple manufacturing suites for single-dose, dual-dose and multi-dose nasal sprays and small volume parenteral fill-finish vials. Its laboratories support R&D formulation development and spray characterization, making Renaissance a complete partner from development through commercial launch.
This acquisition aligns with LTS’ commitment to innovation and excellence in drug delivery. By integrating Renaissance’s capabilities, LTS will be better positioned to serve pharmaceutical and biotechnology partners across a broader spectrum of therapeutic modalities.
Bas van Buijtenen, CEO of LTS, commented: “We are delighted to welcome Renaissance Lakewood to the LTS family. This acquisition marks an important step in our strategy to expand our CDMO capabilities and strengthen our position as a global leader in innovative drug delivery solutions. Renaissance’s expertise in nasal sprays and sterile dosage forms perfectly complements our existing portfolio and will enable us to deliver even more value to our partners and patients around the world. We look forward to working together to drive innovation and provide high-quality solutions across a broader range of therapeutic modalities. »
Serge Maltais, President and CEO of Renaissance added: “I am incredibly proud of what we have built at Renaissance through the hard work and dedication of our employees. Now, as part of the LTS family, our combined strengths will position us even better to meet our customers’ complex needs and deliver greater value to the industry. We are excited to begin this new chapter and look forward to achieving success together.
The transaction is expected to be completed before the end of November 2025, subject to regulatory approvals.
About LTS Lohmann Therapie-Systeme AG
We care. We CREATE. We DELIVER. The driving philosophy behind LTS. As a trusted technology partner to the pharmaceutical industry, we develop and manufacture innovative drug delivery systems such as transdermal patches (“TTS”) and oral thin films (“OTF”) as well as wearable drug delivery devices (“OBDS”). LTS’ commercial offering includes more than 20 marketed products and a diversified portfolio of more than 40 development projects targeting multiple pathological indications. The LTS innovation pipeline contains both partner-funded and proprietary LTS-funded projects. LTS maintains its leadership position through continued refinement of its core TTS and OTF technologies and by advancing emerging drug delivery technologies, including Microneedle Array Patches (“MAPs”) for transdermal delivery of small and large molecules, biologics and vaccines. With its SorrelTM portable drug delivery platform, LTS offers patient-friendly solutions for administering complex medications at home. Founded in 1984, LTS today operates from four locations: Andernach, Germany; West Caldwell, New Jersey, USA; St. Paul, Minnesota, USA; and Netanya, Israel. LTS also has a representative office in Shanghai, China. Learn more about LTS www.ltslohmann.com.
About Renaissance Lakewood, LLC (“Renaissance”)
Renaissance is an American pharmaceutical and biotechnology contract development and manufacturing organization (CDMO). With over 20 years of experience in the field of nasal sprays and sterile dosage forms, Renaissance has a consistent track record of providing exceptional services and resources to its customers from the development phase through commercial launch. Learn more about Renaissance at: www.renpharm.com
For more information, please contact:
LTS Lohmann Therapie-Systeme AG
Dr. Iris Schnitzler: iris.schnitzler@ltslohmann.com; +49 2632 992589
Contact Renaissance Media
media@renpharm.com
732-730-3262
SOURCE LTS Lohmann Therapie-Systeme AG
